Globus Medical, Inc. (GMED) Balance Sheet

The balance sheet has consistently strengthened over the past ten quarters, with equity rising from $3.9B to $4.8B, driven by robust retained earnings. Total liabilities have remained relatively flat, indicating that asset growth is primarily equity-funded. This trajectory suggests the company is generating sufficient internal capital to support its expansion, a sign of improving financial flexibility.

The dramatic reduction in debt, likely from the NuVasive acquisition financing, has left GMED with negligible leverage. This low D/E ratio, compared to peers like Stryker (0.73) and Zimmer Biomet (0.59), provides significant financial flexibility for future investments or acquisitions. The absence of meaningful debt service obligations also reduces refinancing risk and supports cash flow durability.

The asset base is increasingly composed of goodwill and intangibles from the NuVasive and Nevro acquisitions, which now represent a significant portion of total assets. The slight decline in PPE may indicate a more asset-light model, but the high goodwill balance warrants monitoring for potential impairment if integration synergies fail to materialize. The stable goodwill suggests management is not overpaying for acquisitions, but the risk remains.

Equity quality is high, with retained earnings being the primary driver of the $0.9B increase in equity over the period. The company has not paid dividends, instead reinvesting profits and repurchasing shares, as seen in the cash flow statement. This approach supports long-term value creation, though investors should monitor the pace of share repurchases relative to stock-based compensation dilution.

The current ratio of 4.62 is well above the peer average, providing a substantial buffer against operational disruptions or market volatility. Cash levels have fluctuated but remain healthy, supported by strong operating cash flow. This liquidity, combined with minimal debt, positions GMED to weather potential downturns or pursue strategic opportunities without external financing.